The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
ArrayPatch
Dissolving microneedle drug-delivery platform progressing toward first-in-human studies.
What they do
ArrayPatch develops DerMap dissolving microneedle therapeutics, including programs for obesity, diabetes and basal cell carcinoma. On November 5, 2026, it announced a €1.6 million second close, bringing its seed financing total to €3.2 million. Proceeds support development toward first-in-human studies. These are development programs, not approved therapies, and no USD conversion is supplied.
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- Microneedle therapeutics
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- Cork, Ireland
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA
Buying Second Chances: Biossil, Theriva and the AI-Native Bet on Shelved Drugs
Dr. Dereck Mush, MD, MBA